Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(26)00202-3
Affiliations:
5
Authors:
8
Go to article
Institutions Authors Share
Lilly, United States of America (USA)
6.000000
 0.75
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)
1.000000
 0.13
Kyoto University, Japan
0.333333
 0.04
Kansai Electric Power Co., Inc., Japan
0.333333
 0.04
Gifu University, Japan
0.333333
 0.04
Interested in Pharmacology and Pharmaceutical Sciences?